Suhl, S., Lapolla, B., Kaminsky, A., & Geskin, L. J. (2025). Treatment of Sezary syndrome with combination romidepsin and tofacitinib: A case report. JAAD Case Reports, 55, 69–72. https://doi.org/10.1016/j.jdcr.2024.11.007

Falchook, G., Rasco, D., Papadopoulos, K., Parikh, A., Mahipal, A., Messersmith, W., Manji, G., Fu, S., Sherman, E., Fein, D., Krop, J., Korth, C., Wang, J., Sharma, M., Spigel, D., Filipovic, A., & Wainberg, Z. (2023). 128P A phase I dose escalation and expansion trial of LYT-200: A galectin-9 antibody +/- tislelizumab. Immuno-Oncology and Technology, 20, 100600. https://doi.org/10.1016/j.iotech.2023.100600

Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., Dereure, O., Oro, S., Beylot-Barry, M., Dalle, S., Jacobsen, E., Lansigan, F., Ram-Wolff, C., Khodadoust, M. S., Battistella, M., Gru, A. A., Moins-Teisserenc, H., Zinzani, P. L., Viotti, J., … Porcu, P. (2023). Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial. Blood, 142(Supplement 1), 185–185. https://doi.org/10.1182/blood-2023-173806

LaRose, M., Connolly, R. M., O’Sullivan, C. C., Velcheti, V., Vilimas, R., Gano, K., Bates, S. E., Pommier, Y., & Thomas, A. (2023). A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors. The Oncologist, 28(5), 460-e298. https://doi.org/10.1093/oncolo/oyad023

Prince, H. M. M., Geskin, L. J., Akilov, O. E., Kuzel, T. M., Querfeld, C., Ooi, C. E., Xing, D., Sauter, N., Singh, P., Czuczman, M., & Foss, F. M. (2022). Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302. Blood, 140(Supplement 1), 6577–6578. https://doi.org/10.1182/blood-2022-167564

Pemmaraju, N., Cuglievan, B., Lasky, J., Kheradpour, A., Hijiya, N., Stein, A. S., Meshinchi, S., Mullen, C., Angelucci, E., Vinti, L., Mughal, T. I., & Pawlowska, A. (2022). P521: TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY. HemaSphere, 6, 420–421. https://doi.org/10.1097/01.hs9.0000844972.31512.dd